EU regulator reviews reports of rare nervous disorder after AstraZeneca vaccine By Reuters

(Reuters) – Europe’s medicines regulator said on Friday it was reviewing reports of a rare condition affecting the nerves following vaccination with AstraZeneca (NASDAQ:AZN)’s COVID-19 shot, and requested the British drugmaker for more detailed data.

As part of a regular review of safety reports for the vaccine, Vaxzevria, the European Medicines Agency’s safety committee is analysing data provided on cases of Guillain-Barre syndrome, the regulator said.

AstraZeneca did not immediately respond to requests for comment.